

REFERENCES

- Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR: Intravenous iron versus erythropoiesis-stimulating agents: Friends or foes in treating chronic kidney disease anemia? *Adv Chronic Kidney Dis* 16: 143–151, 2009
- Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH: The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? *Clin J Am Soc Nephrol* 1[Suppl 1]: S9–S18, 2006
- Murray MJ, Murray AB, Murray MB, Murray CJ: The adverse effect of iron repletion on the course of certain infections. *BMJ* 2: 1113–1115, 1978
- Waterlot Y, Cantinieaux B, Hariga-Muller C, De Maertelaere-Laurent E, Vanherweghem JL, Fondou P: Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. *Br Med J (Clin Res Ed)* 291: 501–504, 1985
- Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. *Am J Kidney Dis* 40: 90–103, 2002
- Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH: Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. *Am J Kidney Dis* 37: 564–572, 2001
- Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. *Circulation* 106: 2212–2217, 2002
- Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. *J Am Soc Nephrol* 13: 734–744, 2002
- Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. *J Am Soc Nephrol* 15: 1623–1632, 2004
- Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Jankiewicz P, Drahi G, Dahan H, Cohen Y: Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: An MRI study. *Am J Med*. 2012;125:991–999
- Keung YK, Owen J: Iron deficiency and thrombosis: Literature review. *Clin Appl Thromb Hemost* 2004;10:387–391
- Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K: Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. *Am J Kidney Dis* 52: 727–736, 2008
- Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV: A comparison of intravenous iron supplementation strategies and infection risk in hemodialysis patients. *J Am Soc Nephrol*. 24: 1151–1158, 2013
- Kovesdy CP, Kalantar-Zadeh K: Observational studies versus randomized controlled trials: Avenues to causal inference in nephrology. *Adv Chronic Kidney Dis* 19: 11–18, 2012
- Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R: High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. *Circulation* 86: 803–811, 1992
- Sempos CT, Looker AC, Gillum RF, Makuc DM: Body iron stores and the risk of coronary heart disease. *N Engl J Med* 330: 1119–1124, 1994
- Kalantar-Zadeh K, McAllister CJ, Lehn RS, Liu E, Kopple JD: A low serum iron level is a predictor of poor outcome in hemodialysis patients. *Am J Kidney Dis* 43: 671–684, 2004
- Weiss G, Meusbürger E, Radacher G, Garimorth K, Neyer U, Mayer G: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. *Kidney Int* 64: 572–578, 2003

See related article, “Infection Risk with Bolus versus Maintenance Iron Supplementation in Hemodialysis Patients,” on pages 1151–1158.

Ideal Cardiovascular Health and Progression of CKD: Perhaps not so “Simple”

Andrew I. Chin and Lorien S. Dalrymple

Division of Nephrology, Department of Medicine, University of California, Davis, California

J Am Soc Nephrol 24: 1031–1033, 2013.
doi: 10.1681/ASN.2013040388

CKD is a global public health challenge. More than 13 million adults in the United States have moderate to severe CKD.¹ The prevalence of CKD has increased over time, in part due to the higher prevalence of diabetes and hypertension and the aging population.^{2,3} Importantly, elderly adults with CKD are 13-fold more likely to die than reach advanced CKD requiring renal replacement therapy (CKD 5D), with cardiovascular disease being the leading cause of death.⁴ Identifying health behaviors and health factors that lower the risk of progressive kidney dysfunction and death in the CKD population is paramount to optimizing health and longevity. In 2010, the American Heart Association (AHA) published “Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association’s Strategic Impact Goal Through 2020 and Beyond,” wherein the concept of ideal cardiovascular health was defined.⁵ Ideal cardiovascular health is a conceptual framework that includes favorable health behaviors and health factors such as abstinence from smoking, an ideal body mass index (BMI), routine physical activity, a healthy diet, an untreated cholesterol <200 mg/dl, an untreated BP <120/80 mmHg, and the absence of diabetes mellitus. Although these health behaviors and factors define ideal cardiovascular health, these metrics correlate with general health, longevity, and prevention of other chronic diseases including CKD.⁵ The AHA has developed Life’s Simple 7 and the My Life Check,⁶ which focus on optimizing these key modifiable health behaviors and factors.

In this issue of *JASN*, Muntner *et al.*⁷ examined the association between the AHA’s Life’s Simple 7 and the incidence of CKD 5D in Reasons for Geographic and Racial Differences in Stroke (REGARDS) study participants with an estimated GFR (eGFR) <60 ml/min per 1.73 m². All-cause death was examined in secondary analyses. REGARDS participants’ BP, total cholesterol, serum glucose, cigarette smoking, physical activity, diet, and BMI were each classified as poor, intermediate, or

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Lorien S. Dalrymple, Division of Nephrology, University of California, Davis, 4150 V Street, Suite 3500, Sacramento, CA 95817. Email: Lorien.Dalrymple@ucdmc.ucdavis.edu

Copyright © 2013 by the American Society of Nephrology

ideal health. The proportion of participants classified as ideal health varied substantially by health behavior or factor, with <1% of participants classified as ideal for diet and 89% classified as ideal for cigarette smoking. The vast majority of participants (84%) had 1–3 ideal health behaviors or factors, whereas only 3% of participants had ≥ 5 ideal health components. During a median follow-up of 4 years, 160 participants (5%) developed CKD 5D and 610 participants (20%) died. The incidence of CKD 5D ranged from 0 to 22.5 per 1000 person-years, with the lowest incidence in those with ≥ 5 ideal components of Life's Simple 7. In adjusted analyses that accounted for demographics, geographic region, income, education, prevalent stroke, and coronary heart disease, a graded association between the number of ideal factors and the risk of CKD 5D was observed. Participants with 4 ideal health components had an almost 50% lower risk of CKD 5D compared with those with 0–1 ideal health behaviors or factors. However, once eGFR was accounted for in statistical analyses, the association between the number of ideal health components and CKD 5D was attenuated and no longer significant. The association was also attenuated by the inclusion of urine albumin and the direction of the effect changed (*i.e.*, higher hazard ratio with higher number of ideal components), albeit the association was not statistically significant. Interestingly, when only health behaviors (*e.g.*, BMI, cigarette smoking, physical activity, and diet) were examined, no statistically significant association between the number of ideal health behaviors and the risk of incident CKD 5D was observed; however, the direction of the effect was generally protective or neutral. When the association between the number of ideal Life's Simple 7 components and the risk of death was examined, inclusion of eGFR and urine albumin largely attenuated any observed association, similar to the findings with CKD 5D.

The study by Muntner *et al.*⁷ is interesting because Life's Simple 7 represent modifiable health behaviors and factors that have been linked to cardiovascular health and to CKD. Therefore, examining whether Life's Simple 7, a public health campaign by the AHA, are associated with important outcomes in CKD is inherently appealing. The study by Muntner *et al.* provides a thoughtful examination of the association between ideal cardiovascular health and CKD 5D and death in older adults with established CKD. As perhaps expected, the higher the number of ideal cardiovascular health behaviors or factors, the lower the observed incidence of CKD 5D. However, the association between ideal cardiovascular health behaviors and factors and the incidence of CKD 5D was completely attenuated by kidney function and albuminuria, suggesting that kidney function and albuminuria mediate or confound the association between Life's Simple 7 and the incidence of CKD 5D. Given these findings, should we not take the time to encourage our patients living with CKD to engage in a healthier lifestyle? Before drawing any conclusions, we should delineate what we can learn from this study and highlight important findings. First, we note that a large percentage of participants were classified as poor health with

respect to specific components of Life's Simple 7: 46% for physical activity, 40% for BMI, 29% for BP, 15% for glucose, and 82% for diet (with the caveat that 33% had missing dietary data). These observations identify potential areas for intensified efforts and care in the CKD population. Second, the findings with respect to health behaviors are particularly interesting. Although not statistically significant, the direction of effect was generally protective. Perhaps these findings should reinvigorate our interest in health behaviors and stimulate further study of the relation between health behaviors and kidney disease progression. Other important considerations include the older age of participants in this study (72 years) and the mean eGFR of 47 ml/min per 1.73 m²—the observations may have differed in younger cohorts or those with less advanced kidney disease. Furthermore, with respect to the ideal classification for cigarette smoking (defined as none in the last year) and BMI (defined as <25 kg/m²), some participants classified as ideal health may actually have had advanced chronic disease or illness. For example, smoking cessation may occur as a result of occult malignancy or declining health, and a low BMI may be due to unintentional weight loss or malnutrition; if poor health resulted in ideal classification for these health behaviors, then the relation between cardiovascular health and progressive kidney disease or death may be obscured. Finally, this observational study cannot inform our understanding of what would have happened with intervention or modification of health behaviors and factors.

The study by Muntner *et al.*⁷ identifies important opportunities to address and improve health behaviors, especially when considering the large percentage of participants with poor health behaviors. Despite a dearth of definitive data from controlled trials, there are strong arguments for optimizing health behaviors in the CKD population.^{8,9} A review by Johansen and Painter on exercise in patients with CKD provided a clear rationale for exercise and a practical approach to implementing exercise, despite the limitations of the existing literature.¹⁰ Likewise, clear-cut data on smoking cessation and its effectiveness in slowing CKD progression are limited, despite the significant association between smoking and cardiovascular disease in CKD.^{11,12} However, available information suggests that smoking cessation may have positive effects on kidney function.^{13–15}

In conclusion, the study by Muntner *et al.* found that eGFR and albuminuria attenuated the association of Life's Simple 7 with CKD 5D and death. As nephrologists, we can view these findings with either a “glass half full” or a “glass half empty” perspective. We feel that this study provides an opportunity to reconsider and reevaluate our approach to modifying health behaviors and factors in individuals living with CKD. Whether a combination of health behavior changes (*e.g.*, routine exercise, healthy eating, smoking cessation, and attaining ideal body weight) in conjunction with optimal management of health factors (*e.g.*, BP, cholesterol, and glucose) alters the progression of CKD remains a topic worthy of continued study. In the meantime, we suggest taking the optimistic

viewpoint and advocating for a healthy lifestyle in our patients living with CKD.

ACKNOWLEDGMENTS

L.S.D. receives research support from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number K23DK093584. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

DISCLOSURES

None.

REFERENCES

1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. *Ann Intern Med* 150: 604–612, 2009
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. *JAMA* 298: 2038–2047, 2007
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA* 305: 2532–2539, 2011
4. Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L: Chronic kidney disease and the risk of end-stage renal disease versus death. *J Gen Intern Med* 26: 379–385, 2011
5. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD; American Heart Association Strategic Planning Task Force and Statistics Committee: Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation* 121: 586–613, 2010
6. American Heart Association: Life's Simple 7. Available at: <http://mylifecheck.heart.org>. Accessed April 3, 2013
7. Munter P, Judd SE, Gao L, Gutierrez OM, Rizk DV, McClellan W, Cushman M, Warnock DG: Cardiovascular risk factors in CKD associate with both ESRD and mortality. *J Am Soc Nephrol* 24: 1159–1165, 2013
8. Howden EJ, Fassett RG, Isbel NM, Coombes JS: Exercise training in chronic kidney disease patients. *Sports Med* 42: 473–488, 2012
9. Orth SR, Hallan SI: Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients—absence of evidence or evidence of absence? *Clin J Am Soc Nephrol* 3: 226–236, 2008
10. Johansen KL, Painter P: Exercise in individuals with CKD. *Am J Kidney Dis* 59: 126–134, 2012
11. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. *Nephrol Dial Transplant* 12: 2597–2602, 1997
12. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. *JAMA* 293: 1737–1745, 2005
13. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, Hamman RE: Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. *JAMA* 265: 614–617, 1991
14. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M: Smoking is associated with progression of diabetic nephropathy. *Diabetes Care* 17: 126–131, 1994
15. Hallan SI, Orth SR: Smoking is a risk factor in the progression to kidney failure. *Kidney Int* 80: 516–523, 2011

See related article, "Cardiovascular Risk Factors in CKD Associate with Both ESRD and Mortality," on pages 1159–1165.